Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09ZKS
|
|||
| Former ID |
DIB012096
|
|||
| Drug Name |
HP-228
|
|||
| Synonyms |
HP 228; Ac-Nle-gln-his-D-phe-arg-D-trp-gly-NH2; AC1L2XO7; 109022-88-0; Acetyl-norleucyl-glutaminyl-histidyl-phenylalanyl-arginyl-tryptophyl-glycinamide; L-Norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycinamide; Glycinamide, L-norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Postoperative pain [ICD-11: MG30-MG3Z; ICD-10: G89] | Phase 2 | [1] | |
| Company |
LION bioscience Inc
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C47H65N15O9
|
|||
| Canonical SMILES |
CCCCC(C(=O)NC(CCC(=O)N)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N)NC(=O)C
|
|||
| InChI |
1S/C47H65N15O9/c1-3-4-14-33(57-27(2)63)42(67)59-35(17-18-39(48)64)44(69)62-38(22-30-24-52-26-56-30)46(71)60-36(20-28-11-6-5-7-12-28)45(70)58-34(16-10-19-53-47(50)51)43(68)61-37(41(66)55-25-40(49)65)21-29-23-54-32-15-9-8-13-31(29)32/h5-9,11-13,15,23-24,26,33-38,54H,3-4,10,14,16-22,25H2,1-2H3,(H2,48,64)(H2,49,65)(H,52,56)(H,55,66)(H,57,63)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,50,51,53)/t33-,34-,35-,36+,37+,38-/m0/s1
|
|||
| InChIKey |
UHKZNDVUBSEJJO-XAYNKGEHSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nitric-oxide synthase inducible (NOS2) | Target Info | Modulator | [1] |
| BioCyc | Citrulline-nitric oxide cycle | |||
| KEGG Pathway | Arginine biosynthesis | |||
| Arginine and proline metabolism | ||||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| Peroxisome | ||||
| Salmonella infection | ||||
| Pertussis | ||||
| Leishmaniasis | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Toxoplasmosis | ||||
| Amoebiasis | ||||
| Tuberculosis | ||||
| Pathways in cancer | ||||
| Small cell lung cancer | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| Alpha9 beta1 integrin signaling events | ||||
| ATF-2 transcription factor network | ||||
| IL23-mediated signaling events | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | ROS production in response to bacteria | |||
| Nitric oxide stimulates guanylate cyclase | ||||
| WikiPathways | Type II interferon signaling (IFNG) | |||
| Spinal Cord Injury | ||||
| AGE/RAGE pathway | ||||
| Effects of Nitric Oxide | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.